Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
about
B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review.The need for precision medicine clinical trials in childhood asthma: rationale and design of the PUFFIN trial.Systemic White Blood Cell Count as a Biomarker for Chronic Obstructive Pulmonary Disease: Utility and LimitationsThe Challenges of Precision Medicine in COPD.Is It Time to Change the Definition of Acute Exacerbation of Chronic Obstructive Pulmornary Disease? What Do We Need to Add?Precision medicine in COPD: where are we and where do we need to go?
P2860
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
@ast
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
@en
type
label
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
@ast
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
@en
prefLabel
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
@ast
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
@en
P2093
P1433
P1476
Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
@en
P2093
Bruce M McManus
Mari L DeMarco
Raymond T Ng
P304
P356
10.1016/J.CHEST.2016.09.012
P407
P577
2016-09-29T00:00:00Z